Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of CDX-1127 in Patients With Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT01460134
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:36:41.490585+00:00
Published At
2018-01-31T00:00:00+00:00
Record Updated At
2018-01-31
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["CD27 Expressing B-cell Malignancies for Example Hodgkin\u0027s Lymphoma", "Chronic Lymphocytic Leukemia", "Mantle Cell Lymphoma", "Marginal Zone B Cell Lymphoma)", "Any T-cell Malignancy", "Solid Tumors (Metastatic Melanoma, Renal (Clear) Cell Carcinoma", "Hormone-refractory Prostate Adenocarcinoma, Ovarian Cancer", "Colorectal Adenocarcinoma, Non-small Cell Lung Cancer)", "Burkett\u0027s Lymphoma", "Primary Lymphoma of the Central Nervous System"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2018-01-31"
protocolSection.identificationModule.nctId
"NCT01460134"
protocolSection.identificationModule.officialTitle
"A Phase 1, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of CDX-1127 in Patients With Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • CD27 Expressing B-cell Malignancies for Example Hodgkin's Lymphoma (protocolSection.conditionsModule.conditions)
  • Chronic Lymphocytic Leukemia (protocolSection.conditionsModule.conditions)
  • Mantle Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Marginal Zone B Cell Lymphoma) (protocolSection.conditionsModule.conditions)
  • Any T-cell Malignancy (protocolSection.conditionsModule.conditions)
  • Solid Tumors (Metastatic Melanoma, Renal (Clear) Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Hormone-refractory Prostate Adenocarcinoma, Ovarian Cancer (protocolSection.conditionsModule.conditions)
  • Colorectal Adenocarcinoma, Non-small Cell Lung Cancer) (protocolSection.conditionsModule.conditions)
  • Burkett's Lymphoma (protocolSection.conditionsModule.conditions)
  • Primary Lymphoma of the Central Nervous System (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.